| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A851 | Theraclone patent anti-GM-CSF Featured |
|
|
| DC60709 | BAL-0028 Featured | BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity. |
|
| DC67198 | Tulathromycin B Featured | Tulathromycin B (CP 547272) is an isomer of Tulathromycin (a macrolide antibiotic). |
|
| DC67199 | Virginiamycin M1 Featured | Virginiamycin M1 (Pristinamycin IIA; Ostreogrycin A), produced by Streptomyces virginiae, is an polyunsaturated macrocyclic lactone antibiotic and acts as a component of Virginiamycin (HY-112665). Virginiamycin M1 alone is against Staphylococcus aureus with a MIC of 0.25 μg/mL. |
|
| DC67200 | FR179642 hydrate Featured | FR179642 hydrate is the cyclic peptide nucleus of the lipopeptide antifungal FR901379 and an intermediate in the synthesis of the echinocandin antifungal FK463. |
|
| DC67201 | Pneumocandin C0 (9CI) Featured | Pneumocandin C0 is the isomer of Pneumocandin B0 (HY-17578) with antifungal activity, which is found by carrying out fermentations of Glarea lozoyensis at a high residual fructose concentration. |
|
| DC67202 | Pneumocandin E0 Featured |
|
|
| DC67203 | ZERANOL Featured |
|
|
| DC67204 | Chloroorienticin A Featured | Chloroorienticin A (A82846B) is a glycopeptide antibiotic. Chloroorienticin A exhibits excellent activity against staphylococci and streptococci. |
|
| DC67205 | Daunorubicin EP Impurity B Featured |
|
|
| DC67206 | Cp2-S04 Featured |
|
|
| DC67207 | Flecainide hydrochloride Featured | Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na+ current (INa) and the rapid component of the delayed rectifier K+ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias. |
|
| DC67208 | INF 195 Featured | INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury. |
|
| DC67209 | Kif18A-IN-6 Featured | KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity. |
|
| A852 | Mavrilimumab Featured | Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. |
|
| A853 | Trabikibart Featured | Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research. |
|
| A854 | Anumigilimab Featured | Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation. |
|
| A855 | CSL patent anti-G-CSFR Featured |
|
|
| A856 | Quavonlimab Featured | Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody. |
|
| A857 | Zalifrelimab Featured | Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling. |
|
| A858 | SY18-VHH-11 Featured |
|
|
| A859 | CAT-2200 Featured | CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A860 | Ixekizumab Featured | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis. |
|
| A861 | UCB patent anti-IL-17 Featured |
|
|
| A862 | Anti-CTSS/Cathepsin S Antibody (Fsn0503h) Featured |
|
|
| A863 | Quetmolimab Featured | Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion. |
|
| A864 | Lilly patent anti-Pan-ELR+ Featured |
|
|
| A865 | NI-0801 Featured | NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A866 | Eldelumab Featured | Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. |
|
| A867 | Genentech anti-CXCL12 Featured |
|
